Charles River Laboratories International (NYSE:CRL) Rating Lowered to “Hold” at Wall Street Zen

by · The Cerbat Gem

Charles River Laboratories International (NYSE:CRL – Get Free Report) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

Several other research analysts have also issued reports on the stock. JPMorgan Chase & Co. raised their price target on shares of Charles River Laboratories International from $160.00 to $165.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. Jefferies Financial Group upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and increased their price objective for the stock from $142.00 to $195.00 in a research report on Tuesday, September 9th. Morgan Stanley set a $185.00 target price on shares of Charles River Laboratories International in a report on Monday, December 1st. William Blair upgraded Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a report on Monday, October 6th. Finally, Barclays boosted their price objective on Charles River Laboratories International from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $189.38.

Check Out Our Latest Report on CRL

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock opened at $192.95 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64. Charles River Laboratories International has a twelve month low of $91.86 and a twelve month high of $199.66. The stock has a market cap of $9.50 billion, a price-to-earnings ratio of -123.68, a P/E/G ratio of 6.82 and a beta of 1.63. The company’s fifty day moving average is $177.40 and its 200 day moving average is $163.66.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.11. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.Charles River Laboratories International’s revenue for the quarter was down .5% compared to the same quarter last year. During the same period last year, the company earned $2.59 EPS. Sell-side analysts forecast that Charles River Laboratories International will post 9.36 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Brooklyn Investment Group grew its stake in Charles River Laboratories International by 93.5% in the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 86 shares during the period. Cromwell Holdings LLC lifted its holdings in shares of Charles River Laboratories International by 542.9% in the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock worth $27,000 after purchasing an additional 152 shares in the last quarter. Neo Ivy Capital Management bought a new position in shares of Charles River Laboratories International in the 2nd quarter worth $29,000. Rothschild Investment LLC grew its position in Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 84 shares during the period. Finally, Atlantic Union Bankshares Corp bought a new stake in Charles River Laboratories International during the 3rd quarter valued at $31,000. 98.91% of the stock is owned by institutional investors and hedge funds.

About Charles River Laboratories International

(Get Free Report)

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

See Also